LymphedemaV1, Main, Exploration, bibRecordById, PMC:4651262

Late toxicities and outcomes of adjuvant radiotherapy combined with concurrent bevacizumab in patients with triple-negative non-metastatic breast cancer

Identifieur interne : 001C12 ( Main/Exploration ); précédent : 001C11; suivant : 001C13

Late toxicities and outcomes of adjuvant radiotherapy combined with concurrent bevacizumab in patients with triple-negative non-metastatic breast cancer

Auteurs : V. Pernin ; L. Belin ; P. Cottu ; P. Bontemps ; C. Lemanski ; B. De La Lande ; P. Baumann ; F. Missohou ; C. Levy ; K. Peignaux ; A. Reynaud-Bougnoux ; F. Denis ; A. Gobillion ; M. Bollet ; N A Vago ; R. Dendale ; F. Campana ; A. Fourquet ; Y M Kirova

Source :

The British Journal of Radiology [ 0007-1285 ] ; 2015.

RBID : PMC:4651262

Abstract

Objective:

To evaluate the safety of the concurrent combination of bevacizumab with adjuvant radiotherapy (B-RT) in breast cancer (BC).

Methods:

Multicentre, prospective study, of the toxicity of adjuvant radiotherapy (RT) alone or B-RT in patients with non-metastatic BC enrolled in randomized Phase 3 BEATRICE trial. Early and late toxicities were assessed by the Common Terminology Criteria for Adverse Events v. 3.0 during and 12 months after the completion of RT.

Results:

From 2007 to 2012, 39 females received adjuvant B-RT and 45 received adjuvant RT alone. Median follow-up was 21.5 months. All patients had triple-negative non-metastatic BC and received adjuvant chemotherapy followed by RT. 90% of the 39 females treated by concurrent B-RT received whole breast irradiation (WBI) with a boost and 4 (10%) received post-mastectomy RT. Lymph node RT was delivered in 49% of the females with internal mammary chain irradiation. The mean duration of bevacizumab was 11.7 months. 38 (84%) females treated by RT alone received WBI with a boost and 16% of the females received post-mastectomy RT. Lymph node RT was delivered in 47% of the females with internal mammary chain RT in 31%. Grade 3 acute dermatitis was observed in 9% of patients receiving B-RT and 5% of patients receiving RT alone with no significant difference. 1 year after the completion of RT, the most common late grade 1–2 toxicities in the B-RT group were pain (18%), fibrosis (8%) and telangiectasia (5%).

Conclusion:

The concurrent bevacizumab with locoregional RT is associated with acceptable early and late 1-year toxicities in patients with BC.

Advances in knowledge:

The largest series of this association.

Url:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4651262

DOI: 10.1259/bjr.20140800
PubMed: 25645108
PubMed Central: 4651262

Affiliations:

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Late toxicities and outcomes of adjuvant radiotherapy combined with concurrent bevacizumab in patients with triple-negative non-metastatic breast cancer</title>
<author><name sortKey="Pernin, V" sort="Pernin, V" uniqKey="Pernin V" first="V" last="Pernin">V. Pernin</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Belin, L" sort="Belin, L" uniqKey="Belin L" first="L" last="Belin">L. Belin</name>
<affiliation><nlm:aff id="aff2"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Cottu, P" sort="Cottu, P" uniqKey="Cottu P" first="P" last="Cottu">P. Cottu</name>
<affiliation><nlm:aff id="aff3"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Bontemps, P" sort="Bontemps, P" uniqKey="Bontemps P" first="P" last="Bontemps">P. Bontemps</name>
<affiliation><nlm:aff id="aff4"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Lemanski, C" sort="Lemanski, C" uniqKey="Lemanski C" first="C" last="Lemanski">C. Lemanski</name>
<affiliation><nlm:aff id="aff5"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="De La Lande, B" sort="De La Lande, B" uniqKey="De La Lande B" first="B" last="De La Lande">B. De La Lande</name>
<affiliation><nlm:aff id="aff6"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Baumann, P" sort="Baumann, P" uniqKey="Baumann P" first="P" last="Baumann">P. Baumann</name>
<affiliation><nlm:aff id="aff7"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Missohou, F" sort="Missohou, F" uniqKey="Missohou F" first="F" last="Missohou">F. Missohou</name>
<affiliation><nlm:aff id="aff8"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Levy, C" sort="Levy, C" uniqKey="Levy C" first="C" last="Levy">C. Levy</name>
<affiliation><nlm:aff id="aff9"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Peignaux, K" sort="Peignaux, K" uniqKey="Peignaux K" first="K" last="Peignaux">K. Peignaux</name>
<affiliation><nlm:aff id="aff10"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Reynaud Bougnoux, A" sort="Reynaud Bougnoux, A" uniqKey="Reynaud Bougnoux A" first="A" last="Reynaud-Bougnoux">A. Reynaud-Bougnoux</name>
<affiliation><nlm:aff id="aff11"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Denis, F" sort="Denis, F" uniqKey="Denis F" first="F" last="Denis">F. Denis</name>
<affiliation><nlm:aff id="aff12"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Gobillion, A" sort="Gobillion, A" uniqKey="Gobillion A" first="A" last="Gobillion">A. Gobillion</name>
<affiliation><nlm:aff id="aff2"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Bollet, M" sort="Bollet, M" uniqKey="Bollet M" first="M" last="Bollet">M. Bollet</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Vago, N A" sort="Vago, N A" uniqKey="Vago N" first="N A" last="Vago">N A Vago</name>
<affiliation><nlm:aff id="aff13"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Dendale, R" sort="Dendale, R" uniqKey="Dendale R" first="R" last="Dendale">R. Dendale</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Campana, F" sort="Campana, F" uniqKey="Campana F" first="F" last="Campana">F. Campana</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Fourquet, A" sort="Fourquet, A" uniqKey="Fourquet A" first="A" last="Fourquet">A. Fourquet</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Kirova, Y M" sort="Kirova, Y M" uniqKey="Kirova Y" first="Y M" last="Kirova">Y M Kirova</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">25645108</idno>
<idno type="pmc">4651262</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4651262</idno>
<idno type="RBID">PMC:4651262</idno>
<idno type="doi">10.1259/bjr.20140800</idno>
<date when="2015">2015</date>
<idno type="wicri:Area/Pmc/Corpus">000256</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000256</idno>
<idno type="wicri:Area/Pmc/Curation">000256</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000256</idno>
<idno type="wicri:Area/Pmc/Checkpoint">001140</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">001140</idno>
<idno type="wicri:Area/Ncbi/Merge">006F89</idno>
<idno type="wicri:Area/Ncbi/Curation">006F89</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">006F89</idno>
<idno type="wicri:doubleKey">0007-1285:2015:Pernin V:late:toxicities:and</idno>
<idno type="wicri:Area/Main/Merge">001C15</idno>
<idno type="wicri:Area/Main/Curation">001C12</idno>
<idno type="wicri:Area/Main/Exploration">001C12</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Late toxicities and outcomes of adjuvant radiotherapy combined with concurrent bevacizumab in patients with triple-negative non-metastatic breast cancer</title>
<author><name sortKey="Pernin, V" sort="Pernin, V" uniqKey="Pernin V" first="V" last="Pernin">V. Pernin</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Belin, L" sort="Belin, L" uniqKey="Belin L" first="L" last="Belin">L. Belin</name>
<affiliation><nlm:aff id="aff2"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Cottu, P" sort="Cottu, P" uniqKey="Cottu P" first="P" last="Cottu">P. Cottu</name>
<affiliation><nlm:aff id="aff3"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Bontemps, P" sort="Bontemps, P" uniqKey="Bontemps P" first="P" last="Bontemps">P. Bontemps</name>
<affiliation><nlm:aff id="aff4"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Lemanski, C" sort="Lemanski, C" uniqKey="Lemanski C" first="C" last="Lemanski">C. Lemanski</name>
<affiliation><nlm:aff id="aff5"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="De La Lande, B" sort="De La Lande, B" uniqKey="De La Lande B" first="B" last="De La Lande">B. De La Lande</name>
<affiliation><nlm:aff id="aff6"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Baumann, P" sort="Baumann, P" uniqKey="Baumann P" first="P" last="Baumann">P. Baumann</name>
<affiliation><nlm:aff id="aff7"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Missohou, F" sort="Missohou, F" uniqKey="Missohou F" first="F" last="Missohou">F. Missohou</name>
<affiliation><nlm:aff id="aff8"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Levy, C" sort="Levy, C" uniqKey="Levy C" first="C" last="Levy">C. Levy</name>
<affiliation><nlm:aff id="aff9"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Peignaux, K" sort="Peignaux, K" uniqKey="Peignaux K" first="K" last="Peignaux">K. Peignaux</name>
<affiliation><nlm:aff id="aff10"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Reynaud Bougnoux, A" sort="Reynaud Bougnoux, A" uniqKey="Reynaud Bougnoux A" first="A" last="Reynaud-Bougnoux">A. Reynaud-Bougnoux</name>
<affiliation><nlm:aff id="aff11"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Denis, F" sort="Denis, F" uniqKey="Denis F" first="F" last="Denis">F. Denis</name>
<affiliation><nlm:aff id="aff12"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Gobillion, A" sort="Gobillion, A" uniqKey="Gobillion A" first="A" last="Gobillion">A. Gobillion</name>
<affiliation><nlm:aff id="aff2"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Bollet, M" sort="Bollet, M" uniqKey="Bollet M" first="M" last="Bollet">M. Bollet</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Vago, N A" sort="Vago, N A" uniqKey="Vago N" first="N A" last="Vago">N A Vago</name>
<affiliation><nlm:aff id="aff13"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Dendale, R" sort="Dendale, R" uniqKey="Dendale R" first="R" last="Dendale">R. Dendale</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Campana, F" sort="Campana, F" uniqKey="Campana F" first="F" last="Campana">F. Campana</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Fourquet, A" sort="Fourquet, A" uniqKey="Fourquet A" first="A" last="Fourquet">A. Fourquet</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Kirova, Y M" sort="Kirova, Y M" uniqKey="Kirova Y" first="Y M" last="Kirova">Y M Kirova</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
</analytic>
<series><title level="j">The British Journal of Radiology</title>
<idno type="ISSN">0007-1285</idno>
<idno type="eISSN">1748-880X</idno>
<imprint><date when="2015">2015</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><sec><title>Objective:</title>
<p>To evaluate the safety of the concurrent combination of bevacizumab with adjuvant radiotherapy (B-RT) in breast cancer (BC).</p>
</sec>
<sec><title>Methods:</title>
<p>Multicentre, prospective study, of the toxicity of adjuvant radiotherapy (RT) alone or B-RT in patients with non-metastatic BC enrolled in randomized Phase 3 BEATRICE trial. Early and late toxicities were assessed by the Common Terminology Criteria for Adverse Events v. 3.0 during and 12 months after the completion of RT.</p>
</sec>
<sec><title>Results:</title>
<p>From 2007 to 2012, 39 females received adjuvant B-RT and 45 received adjuvant RT alone. Median follow-up was 21.5 months. All patients had triple-negative non-metastatic BC and received adjuvant chemotherapy followed by RT. 90% of the 39 females treated by concurrent B-RT received whole breast irradiation (WBI) with a boost and 4 (10%) received post-mastectomy RT. Lymph node RT was delivered in 49% of the females with internal mammary chain irradiation. The mean duration of bevacizumab was 11.7 months. 38 (84%) females treated by RT alone received WBI with a boost and 16% of the females received post-mastectomy RT. Lymph node RT was delivered in 47% of the females with internal mammary chain RT in 31%. Grade 3 acute dermatitis was observed in 9% of patients receiving B-RT and 5% of patients receiving RT alone with no significant difference. 1 year after the completion of RT, the most common late grade 1–2 toxicities in the B-RT group were pain (18%), fibrosis (8%) and telangiectasia (5%).</p>
</sec>
<sec><title>Conclusion:</title>
<p>The concurrent bevacizumab with locoregional RT is associated with acceptable early and late 1-year toxicities in patients with BC.</p>
</sec>
<sec><title>Advances in knowledge:</title>
<p>The largest series of this association.</p>
</sec>
</div>
</front>
</TEI>
<affiliations><list></list>
<tree><noCountry><name sortKey="Baumann, P" sort="Baumann, P" uniqKey="Baumann P" first="P" last="Baumann">P. Baumann</name>
<name sortKey="Belin, L" sort="Belin, L" uniqKey="Belin L" first="L" last="Belin">L. Belin</name>
<name sortKey="Bollet, M" sort="Bollet, M" uniqKey="Bollet M" first="M" last="Bollet">M. Bollet</name>
<name sortKey="Bontemps, P" sort="Bontemps, P" uniqKey="Bontemps P" first="P" last="Bontemps">P. Bontemps</name>
<name sortKey="Campana, F" sort="Campana, F" uniqKey="Campana F" first="F" last="Campana">F. Campana</name>
<name sortKey="Cottu, P" sort="Cottu, P" uniqKey="Cottu P" first="P" last="Cottu">P. Cottu</name>
<name sortKey="De La Lande, B" sort="De La Lande, B" uniqKey="De La Lande B" first="B" last="De La Lande">B. De La Lande</name>
<name sortKey="Dendale, R" sort="Dendale, R" uniqKey="Dendale R" first="R" last="Dendale">R. Dendale</name>
<name sortKey="Denis, F" sort="Denis, F" uniqKey="Denis F" first="F" last="Denis">F. Denis</name>
<name sortKey="Fourquet, A" sort="Fourquet, A" uniqKey="Fourquet A" first="A" last="Fourquet">A. Fourquet</name>
<name sortKey="Gobillion, A" sort="Gobillion, A" uniqKey="Gobillion A" first="A" last="Gobillion">A. Gobillion</name>
<name sortKey="Kirova, Y M" sort="Kirova, Y M" uniqKey="Kirova Y" first="Y M" last="Kirova">Y M Kirova</name>
<name sortKey="Lemanski, C" sort="Lemanski, C" uniqKey="Lemanski C" first="C" last="Lemanski">C. Lemanski</name>
<name sortKey="Levy, C" sort="Levy, C" uniqKey="Levy C" first="C" last="Levy">C. Levy</name>
<name sortKey="Missohou, F" sort="Missohou, F" uniqKey="Missohou F" first="F" last="Missohou">F. Missohou</name>
<name sortKey="Peignaux, K" sort="Peignaux, K" uniqKey="Peignaux K" first="K" last="Peignaux">K. Peignaux</name>
<name sortKey="Pernin, V" sort="Pernin, V" uniqKey="Pernin V" first="V" last="Pernin">V. Pernin</name>
<name sortKey="Reynaud Bougnoux, A" sort="Reynaud Bougnoux, A" uniqKey="Reynaud Bougnoux A" first="A" last="Reynaud-Bougnoux">A. Reynaud-Bougnoux</name>
<name sortKey="Vago, N A" sort="Vago, N A" uniqKey="Vago N" first="N A" last="Vago">N A Vago</name>
</noCountry>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001C12 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001C12 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    LymphedemaV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     PMC:4651262
   |texte=   Late toxicities and outcomes of adjuvant radiotherapy combined with concurrent bevacizumab in patients with triple-negative non-metastatic breast cancer
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:25645108" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a LymphedemaV1

This area was generated with Dilib version V0.6.31.
Data generation: Sat Nov 4 17:40:35 2017. Site generation: Tue Feb 13 16:42:16 2024

Serveur d'exploration sur le lymphœdème

Late toxicities and outcomes of adjuvant radiotherapy combined with concurrent bevacizumab in patients with triple-negative non-metastatic breast cancer

Late toxicities and outcomes of adjuvant radiotherapy combined with concurrent bevacizumab in patients with triple-negative non-metastatic breast cancer

Source :

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	Serveur d'exploration sur le lymphœdème
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.